Cell Death and Disease Submission Guide

Source: Cell Death and Disease Guide to Authors and editorial process (read 2026-10-09).

Use this page when deciding:

• whether the disease-mechanism contribution is substantive

• whether functional validation is rigorous

• whether translational relevance is direct

• a clear disease-mechanism contribution

• rigorous functional validation

• in-vivo or clinical validation

• translational relevance

• a cover letter establishing the contribution

• Descriptive cell-death observations without disease relevance.

• Weak functional or in-vivo validation.

• Missing translational connection.

• Basic cell biology without disease focus.

Cell Death and Disease is a flagship cell-death-in-disease journal.

Disease-focus standard: the journal differentiates from Cell Death and Differentiation (basic cell-death biology) by demanding disease relevance.

Functional and in-vivo expectation: editors expect functional and in-vivo or clinical evidence.

Desk rejection: the journal publishes no rate, and the editorial screen is decisive.

The strongest Cell Death and Disease editor-facing notes establish:

• the disease-mechanism contribution

• the functional validation

• the in-vivo or clinical evidence

• the translational relevance

Cell Death and Disease manuscripts move through a four-stage editorial timeline. Knowing the realistic shape of this window prevents authors from misinterpreting silence as a negative signal. The journal publishes no stage-by-stage timings; its information page reports a median of 7 days from submission to first editorial decision and 192 days from submission to acceptance (read 2026-10-09). The stages below describe the sequence only; the journal publishes no timings for them.

Editorial quality check

The editorial office performs an initial quality check that the paper is formatted correctly; Springer Nature describes the check as covering authorship, competing interests, ethics approval and plagiarism.

Editor assignment and triage decision

An Editor is assigned and decides whether to send the manuscript for external peer review. Papers judged of insufficient general interest, weak disease-mechanism contribution, or scope mismatch are rejected without external review at this stage. The Editor-in-Chief contacts the author directly with desk-rejection decisions.

External peer review

Manuscripts sent for review are evaluated by at least one independent reviewer, often two or more. Reviewers are given 14 days from acceptance to submit their reports. Reviewer turnaround is the largest source of timeline variance.

Decision and revision

The handling editor synthesizes reviewer reports and returns a decision. Most decisions are major revision, minor revision, or rejection. Revised submissions require both a rebuttal letter and a marked-up manuscript highlighting changes.

• Is Cell Death and Disease a good journal?

• Cell Death and Differentiation submission guide

Before upload, run your manuscript through a Cell Death and Disease mechanism readiness check.

Public rules are here. Fit is a separate judgement. The review tells you whether your paper clears the Cell Death and Disease fit check before upload, especially around cell-death pathway story without a disease decision, functional evidence that proves a marker change but not disease relevance, and cover letter that cannot explain why this is not Cell Death and Differentiation. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Across cell-death-disease manuscripts targeting Cell Death and Disease, three failure modes account for many early rejections. They are visible in the abstract, figures, disease model, functional validation, translational framing, supplementary files, and cover letter before the submission reaches external reviewers.

Cell-death pathway story without a disease decision

Across Manusights submission reviews for cancer, neurodegeneration, cardiovascular, immune, metabolic, and inflammatory-disease manuscripts targeting Cell Death and Disease, the most common failure is not weak cell biology. It is unclear disease ownership. The abstract describes apoptosis, autophagy, necroptosis, ferroptosis, pyroptosis, or senescence; the figures show pathway markers; the methods use cultured cells or a disease model; but the cover letter does not explain what disease mechanism, therapeutic vulnerability, biomarker interpretation, or translational decision the work changes.

The stronger package makes the disease claim visible from page one. The abstract should name the disease context and the specific cell-death mechanism under test. The main figures should connect pathway manipulation to a disease-relevant phenotype, not only to marker shifts. The methods should explain why the model, patient material, organoid, animal system, or perturbation strategy is appropriate for the disease claim. The discussion should avoid broad therapeutic language unless the evidence supports it.

Cell Death and Disease is a better target when Cell Death and Differentiation would be too basic, Oncogene or Cancer Letters would be too cancer-specific, Molecular Therapy would overemphasize intervention, and Scientific Reports would understate the disease-mechanism contribution.

If your manuscript still reads like general cell-death biology, it may need a different journal or more disease evidence. A Cell Death and Disease mechanism readiness check can identify whether the abstract, figures, methods, and cover letter support the disease-mechanism claim.

Check cell death pathway story without a disease decision before submitting to Cell Death and Disease →

Functional evidence that proves a marker change but not disease relevance

Many Cell Death and Disease submissions include functional assays, but the assays do not always support the manuscript's translational language. We see this when viability, apoptosis marker, ROS, mitochondrial, autophagy, or pathway-readout figures are interpreted as disease mechanism without showing that the same perturbation changes a disease-relevant phenotype. The cover letter may claim therapeutic implication, but the methods and supplementary files only prove that a pathway changes under artificial conditions.

The stronger evidence package asks what the disease reader needs to believe. If the paper claims therapeutic relevance, the figures should show dose, timing, rescue, comparator, or model evidence that connects the mechanism to disease behavior. If it claims biomarker relevance, the methods should show patient-sample logic, cohort interpretation, or disease-stage reasoning. If it claims mechanism, the manuscript should not rely only on inhibitor data without genetic or orthogonal confirmation. The cover letter should state exactly which manuscript component proves disease relevance.

This distinction matters because Cell Death and Disease sits between basic cell-death mechanism and translational disease biology. A paper can be technically competent and still be wrong for the journal if the disease connection is late, decorative, or overstated. Conversely, a focused manuscript with modest scope can be a strong fit if the figures and methods prove a clear disease-linked cell-death mechanism.

Check functional evidence that proves a marker change but not disease relevance before submitting to Cell Death and Disease →

Cover letter that cannot explain why this is not Cell Death and Differentiation

The Cell Death family creates a specific routing problem. We often see Cell Death and Disease submissions whose cover letters describe a cell-death mechanism but do not explain why the disease-focused journal, rather than Cell Death and Differentiation, owns the paper. The reverse also happens: authors submit disease-adjacent work here when the evidence is actually a basic mechanism story. Editors can see this mismatch quickly because the title, abstract, figure order, and cover letter point to different audiences.

The stronger letter makes the route explicit. It should say why the disease context is central, which disease-relevant manuscript component carries the claim, and why adjacent venues such as Cell Death and Differentiation, Oncogene, Cancer Letters, Molecular Therapy, or Journal of Experimental Medicine are less precise. It should also avoid claiming clinical translation if the manuscript only has cultured-cell data. A disciplined cover letter can prevent a good manuscript from being read as basic cell biology wearing a disease label.

When the route is right, the whole package aligns: the abstract names a disease mechanism, the figures prove functional relevance, the methods support the model choice, the supplementary files carry confirmatory evidence, and the references show awareness of recent Cell Death and Disease work.

Check disease mechanism substance before submitting to Cell Death and Disease →

Of the Cell Death and Disease manuscripts we pre-screen, the work that clears the desk advances understanding of cell death biology with rigorous mechanistic support and a clear disease connection, while the work that stalls is sound but its mechanism or disease relevance is thin. The journal is focused on cell death in the context of disease, so reviewers expect both the cell-biology rigor and the disease significance to be solid. Submit if your study delivers a mechanistic cell-death advance with disease relevance; think twice if the mechanism is incomplete or the disease link is loose.

This page was researched from Cell Death and Disease's author guidelines, Springer Nature editorial-policy materials, Clarivate JCR data, SciRev community reports, and our pre-submission review work on submissions to Cell Death and Disease and adjacent venues.

Source limitations: Springer Nature publishes the current guide to authors, editorial policies, open-access model, and submission workflow. It does not publish manuscript-level desk-screen notes. Manusights observations are anonymized pre-submission review patterns and are included only as practical author guidance.

After the official guidance, the practical screen is the set of failure patterns we see when the abstract, figures, disease model, functional validation, translational evidence, supplementary files, and cover letter do not connect cell death to disease.